MX2015011433A - Formulaciones con oxidacion reducida. - Google Patents
Formulaciones con oxidacion reducida.Info
- Publication number
- MX2015011433A MX2015011433A MX2015011433A MX2015011433A MX2015011433A MX 2015011433 A MX2015011433 A MX 2015011433A MX 2015011433 A MX2015011433 A MX 2015011433A MX 2015011433 A MX2015011433 A MX 2015011433A MX 2015011433 A MX2015011433 A MX 2015011433A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- protein
- methods
- oxidation
- reduced oxidation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Lubricants (AREA)
Abstract
La invención proporciona formulaciones que comprenden una proteína en combinación con un compuesto que impide la oxidación de la proteína. La invención también proporciona métodos para elaborar estas formulaciones y métodos para usar estas formulaciones. La invención proporciona además métodos para examinar compuestos para impedir la oxidación de una proteína en una composición de proteína y métodos para prevenir la oxidación de una proteína en una formulación.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780852P | 2013-03-13 | 2013-03-13 | |
US201361909850P | 2013-11-27 | 2013-11-27 | |
PCT/US2014/026850 WO2014160497A1 (en) | 2013-03-13 | 2014-03-13 | Formulations with reduced oxidation |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015011433A true MX2015011433A (es) | 2016-04-27 |
MX370416B MX370416B (es) | 2019-12-10 |
Family
ID=51625443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015011433A MX370416B (es) | 2013-03-13 | 2014-03-13 | Formulaciones con oxidacion reducida. |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP2968467B1 (es) |
JP (2) | JP6606059B2 (es) |
KR (2) | KR102238379B1 (es) |
CN (1) | CN105209058A (es) |
BR (1) | BR112015022475A8 (es) |
CA (2) | CA2904169C (es) |
DK (1) | DK2968467T3 (es) |
ES (1) | ES2808823T3 (es) |
HK (1) | HK1212613A1 (es) |
HR (1) | HRP20201161T1 (es) |
HU (1) | HUE049707T2 (es) |
LT (1) | LT2968467T (es) |
MX (1) | MX370416B (es) |
PL (1) | PL2968467T3 (es) |
PT (1) | PT2968467T (es) |
RS (1) | RS60534B1 (es) |
RU (2) | RU2707550C2 (es) |
SI (1) | SI2968467T1 (es) |
WO (1) | WO2014160497A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108136039A (zh) | 2015-08-18 | 2018-06-08 | 阿斯皮利安治疗学股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
WO2017031363A2 (en) * | 2015-08-18 | 2017-02-23 | Aspyrian Therapeutics, Inc. | Methods for manufacturing phthalocyanine dye conjugates and stable conjugates |
TW202019478A (zh) | 2018-08-08 | 2020-06-01 | 美商建南德克公司 | 色胺酸衍生物及l-甲硫胺酸用於蛋白質調配之用途 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
RU2134120C1 (ru) * | 1995-06-26 | 1999-08-10 | Безруков Михаил Васильевич | Средство для стабилизации пептидной связи в белковом препарате |
ES2332893T3 (es) | 1996-08-30 | 2010-02-15 | Upfront Chromatography A/S | Aislamiento de inmunoglobulinas. |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
US20080318254A9 (en) | 1997-03-10 | 2008-12-25 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
EP1167537B1 (en) | 1999-03-30 | 2008-07-23 | Japan Tobacco Inc. | Process for producing monoclonal antibody |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
IL149008A0 (en) * | 1999-10-04 | 2002-11-10 | Chiron Corp | Stabilized liquid polypeptide-containing pharmaceutical compositions |
JP2001165858A (ja) * | 1999-12-06 | 2001-06-22 | Bunshi Biophotonics Kenkyusho:Kk | 5−アルコキシインドール類の測定方法及び装置 |
CA2447114A1 (en) | 2001-05-16 | 2002-11-21 | Abgenix, Inc. | Human antipneumococcal antibodies from non-human animals |
EP1425389B1 (en) | 2001-08-23 | 2011-11-02 | Genmab A/S | Human antibodies specific for interleukin 15 (il-15) |
WO2004007520A2 (en) * | 2002-07-12 | 2004-01-22 | Medarex, Inc. | Methods and compositions for preventing oxidative degradation of proteins |
AU2004205898B2 (en) | 2003-01-17 | 2009-11-19 | The Research Foundation Of State University Of New York | Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
CA2526398C (en) | 2003-05-21 | 2014-07-15 | Medarex, Inc. | Human monoclonal antibodies against bacillus anthracis protective antigen |
CN101074208A (zh) * | 2007-06-29 | 2007-11-21 | 方炳良 | 吲哚衍生物的制备方法 |
RU2414237C2 (ru) * | 2008-04-30 | 2011-03-20 | Государственное образовательное учреждение высшего профессионального образования "Удмуртский государственный университет" | Модификация альбумина совиалем как способ повышения его стабильности для производства фармацевтического биопрепарата альбумина в комплексе с гентамицином или стимаденом |
CA2734275A1 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
WO2014160495A1 (en) * | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Formulations with reduced oxidation |
-
2014
- 2014-03-13 CA CA2904169A patent/CA2904169C/en active Active
- 2014-03-13 RU RU2015143549A patent/RU2707550C2/ru active
- 2014-03-13 BR BR112015022475A patent/BR112015022475A8/pt not_active Application Discontinuation
- 2014-03-13 CA CA3135558A patent/CA3135558A1/en not_active Abandoned
- 2014-03-13 DK DK14776479.9T patent/DK2968467T3/da active
- 2014-03-13 KR KR1020157027939A patent/KR102238379B1/ko active IP Right Grant
- 2014-03-13 WO PCT/US2014/026850 patent/WO2014160497A1/en active Application Filing
- 2014-03-13 PL PL14776479T patent/PL2968467T3/pl unknown
- 2014-03-13 SI SI201431625T patent/SI2968467T1/sl unknown
- 2014-03-13 ES ES14776479T patent/ES2808823T3/es active Active
- 2014-03-13 MX MX2015011433A patent/MX370416B/es active IP Right Grant
- 2014-03-13 HU HUE14776479A patent/HUE049707T2/hu unknown
- 2014-03-13 PT PT147764799T patent/PT2968467T/pt unknown
- 2014-03-13 LT LTEP14776479.9T patent/LT2968467T/lt unknown
- 2014-03-13 CN CN201480027210.8A patent/CN105209058A/zh active Pending
- 2014-03-13 RS RS20200848A patent/RS60534B1/sr unknown
- 2014-03-13 EP EP14776479.9A patent/EP2968467B1/en active Active
- 2014-03-13 RU RU2019137020A patent/RU2019137020A/ru unknown
- 2014-03-13 KR KR1020217009995A patent/KR102317151B1/ko active IP Right Grant
- 2014-03-13 JP JP2016502264A patent/JP6606059B2/ja active Active
-
2016
- 2016-01-20 HK HK16100589.9A patent/HK1212613A1/zh unknown
-
2019
- 2019-05-08 JP JP2019088239A patent/JP2019167349A/ja active Pending
-
2020
- 2020-07-24 HR HRP20201161TT patent/HRP20201161T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2904169C (en) | 2021-12-07 |
CA2904169A1 (en) | 2014-10-02 |
RU2707550C2 (ru) | 2019-11-27 |
RS60534B1 (sr) | 2020-08-31 |
HRP20201161T1 (hr) | 2020-11-13 |
SI2968467T1 (sl) | 2020-11-30 |
CA3135558A1 (en) | 2014-10-02 |
BR112015022475A8 (pt) | 2019-11-26 |
LT2968467T (lt) | 2020-08-25 |
ES2808823T3 (es) | 2021-03-02 |
RU2019137020A (ru) | 2021-01-14 |
DK2968467T3 (da) | 2020-08-10 |
PL2968467T3 (pl) | 2020-10-19 |
WO2014160497A1 (en) | 2014-10-02 |
JP6606059B2 (ja) | 2019-11-13 |
KR20210040190A (ko) | 2021-04-12 |
PT2968467T (pt) | 2020-07-28 |
JP2016513667A (ja) | 2016-05-16 |
HUE049707T2 (hu) | 2020-11-30 |
RU2015143549A (ru) | 2017-04-20 |
KR20150130396A (ko) | 2015-11-23 |
JP2019167349A (ja) | 2019-10-03 |
HK1212613A1 (zh) | 2016-06-17 |
KR102317151B1 (ko) | 2021-10-26 |
BR112015022475A2 (pt) | 2017-07-18 |
EP2968467A4 (en) | 2016-09-21 |
EP2968467A1 (en) | 2016-01-20 |
MX370416B (es) | 2019-12-10 |
CN105209058A (zh) | 2015-12-30 |
KR102238379B1 (ko) | 2021-04-09 |
EP2968467B1 (en) | 2020-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY191169A (en) | Anti-fcrh5 antibodies | |
HK1247854A1 (zh) | 混合變應原組合物及其使用方法 | |
CL2016002772A1 (es) | Composiciones de insulina de rápida acción | |
MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
WO2015038796A3 (en) | Secretion of heme-containing polypeptides | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
SG10201913040SA (en) | Compositions and methods for stabilizing flaviviruses with improved formulations | |
WO2015120062A8 (en) | Therapeutic compounds and compositions | |
IN2015DN00127A (es) | ||
PL3411432T3 (pl) | Kompozycja wulkanizująca zawierająca cyklododekasiarkę i ulepszony związek cyklododekasiarki | |
MX2019013560A (es) | Formulaciones con oxidacion reducida. | |
PH12017502028A1 (en) | Vortioxetine pyroglutamate | |
AR095398A1 (es) | Formulaciones con oxidación reducida | |
EP3297440A4 (en) | COMPOSITION WITH CARBOPLATIN AND USE | |
IN2014DN11078A (es) | ||
SG10201900598TA (en) | Factor viii formulation | |
EP3527225A4 (en) | COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENT | |
EP3153492A4 (en) | Novel compound and fragrance composition containing same | |
GEP20217236B (en) | Composition comprising pentose and polyphenolic compound | |
MX2015011433A (es) | Formulaciones con oxidacion reducida. | |
PH12017502148A1 (en) | Pharmaceutical compositions and use thereof | |
PL3568203T3 (pl) | Związki i kompozycje | |
BR112017001483A2 (pt) | “composições nutricionais contendo pó de fosfatidilserina” | |
EP3570833A4 (en) | ANESTHETIC COMPOSITIONS AND PROCEDURES USING IMIDAZOLINE COMPOUNDS | |
EP3334808A4 (en) | IMPROVED ANTI-OXIDANT COMPOSITIONS AND LUBRICATING COMPOSITIONS CONTAINING SAME |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |